Page last updated: 2024-11-13

cpu 23

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CPU 23: structure given in first source; naming is inconsistent, may be 2-(2-(6-methoxyl)) group instead of 1(1-(6-methoxyl)) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21151168
MeSH IDM0208493

Synonyms (11)

Synonym
1-(1-(6-methoxynaphth-2-yl))propyl-2-(1-piperidine)acetyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline
132836-32-9
unii-i70amk7u6c
i70amk7u6c ,
isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(1-(6-methoxy-2-naphthalenyl)ethyl)-2-(1-piperidinylacetyl)-
cpu-23
cpu 23
ethanone, 1-(3,4-dihydro-6,7-dimethoxy-1-(1-(6-methoxy-2-naphthalenyl)ethyl)-2(1h)-isoquinolinyl)-2-(1-piperidinyl)-
Q27280521
1-[6,7-dimethoxy-1-[1-(6-methoxynaphthalen-2-yl)ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-2-piperidin-1-ylethanone
PD161043
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.74 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index61.94 (26.88)
Search Engine Supply Index2.95 (0.95)

This Compound (34.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]